£60.0M
The robotics and data intelligence firm secured the capital from a syndicate led by DTCP to expand its artificial intelligence platform and global footprint.
"We are incredibly excited about the momentum we’ve built over the past 18 months,"
A
Atomico
Venture CapitalAtomico manages funds supporting early-stage and growth-stage European technology companies.
Recent investments
$30.0M
The financing round was led by Atomico and will support product development for Windows and iOS.
"Thomas and Petr have built an incredible product that solves a crucial problem not only beautifully, but also effectively with a thriving open-source community of developers at its heart. Raycast provides users with virtually limitless opportunities to build a highly personalised productivity platform tailored to their unique workflows. I personally find it indispensable for my daily work. This is further underscored by the remarkable results of our in-depth user research during due diligence, where a staggering 98% of respondents reported a significant increase in their Raycast usage over the past six months."
£10.5M
The London-based energy platform has raised £10.5m from Atomico and other backers to expand access to renewable power.
"Small and medium-sized businesses are critical in tackling climate change, and are desperate for energy they can trust after seeing their bills soar"
£10.5M
The Series A round was led by Atomico with participation from AlbionVC, Revent, and prominent angel investors.
"working with tem, we are now paying less for fully traceable renewable energy, while putting more money back into the pockets of generators, hugely helping our business reduce its carbon footprint – which is a high priority for our company."
£37.0M
The Series C round was co-led by R42 Group and Atomico to support clinical trials for rare disease treatments.
"It is truly a pivotal time at Healx. By December 2024, we will advance HLX-1502 into a Phase 2 clinical trial in patients with NF1 both for plexiform neurofibroma, a genetic condition with limited treatment options and for cutaneous neurofibroma, for which there are no FDA approved options. We are also generating important preclinical data for multiple additional compounds identified using our novel generative AI drug discovery engine. Those compounds target rare diseases with significant unmet needs, including additional nerve-related tumor disorders, autosomal dominant polycystic kidney disease and neurodevelopmental disorders such as Angelman syndrome."
